Shares in CSL have risen modestly in August amid ongoing volatility, with investors awaiting the upcoming FY26 results to determine if a sustained recovery is on the horizon amid mixed analyst outlooks and sector pressures.
CSL shares have staged a modest recovery this month, but the biopharmaceutical group is still nursing a heavy loss after a bruising year for the stock. The Motley Fool said the shares have risen about 8% in August, yet they remain sharply lower in 2026 and over the past 12 months, leaving investors focused on whether the company’s upcoming full-year results can mark a real turning point.
That question should come into sharper focus on August 18, when CSL is due to report its FY26 numbers. Analyst opinion remains divided. TradingView data quoted by The Motley Fool shows most analysts still sit at hold, while a smaller group remains positive, with the average target price implying only limited upside from current levels. StockAnalysis puts the consensus target a little higher, at A$138.49, and says the market is broadly leaning towards a buy view.
The bigger issue is whether CSL can show that pressure on its main businesses is easing. The Motley Fool reported in May that the company expected FY26 net profit after tax and amortisation of about US$3.1 billion, but investors are likely to look beyond that headline figure. CSL Behring has been hit by lower channel inventory in the US immunoglobulin market and weaker albumin pricing in China, while CSL Vifor has also faced regulatory and commercial setbacks. Jefferies recently cut its recommendation on CSL to hold and lowered its target sharply, citing a weaker FY27 outlook tied to those divisions.
There is, however, still a case for a rebound if the group can show steadier trading in its core franchises. UBS and Morgans remain more constructive than some peers, pointing to resilient demand for immunoglobulin, early signs of improvement in albumin and the possibility that CSL can regain market share. Investors will also be watching the planned demerger of Seqirus, the influenza vaccine arm, which CSL says should be completed by the end of FY26 and could give the separate businesses a clearer strategic focus. For now, CSL remains a turnaround story, and the August result is likely to determine whether the latest bounce has legs or proves to be another false dawn.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
